Marketing content

Why invest in Resonandina?

The Resonandina bond offers exposure to a profitable medical leasing company with recurring revenues, tangible medical projects and a clear impact in cancer care. The points below highlight why this opportunity may be interesting for investors and link to sections with more detail.

1

Profitable company with recurring revenues

Resonandina generates recurring income from long-term pay-per-use contracts and has reported positive EBITDA and net profit in recent years. A growing number of advanced diagnostic scanners and cancer treatment systems supports the company’s recurring revenues.

Read more
2

Growing footprint in under-served markets

Through subsidiaries across Latin America, Resonandina focuses on regions with limited diagnostic and radiotherapy capacity. Each new installation adds local treatment capacity and creates a long-term revenue stream for the group.

Read more
3

Fixed-interest, 4-year bond with clear terms

The bond runs for 4 years with a fixed 9.20% yearly interest, paid together with principal every six months, and a nominal value of €250 per bond. The total round size of €500,000–€2,500,000 enables the Linac project in Colombia to be partly or fully financed..

Read more
4

Measurable impact in cancer care

The financed Linac project in Colombia strengthens local radiotherapy capacity and supports SDG 3 (Good health and wellbeing). Bringing treatment closer to patients can reduce travel distances and support more timely cancer therapy.

Read more
5

Experienced founder-led team and strong partners

Resonandina is led by an experienced management team with backgrounds in medicine, hospital management and project finance. The company works with leading equipment manufacturers such as GE Healthcare and Varian/Siemens Healthineers and certified local service providers.

Read more
6

Crowdfunding as part of a diversified funding base

Since 2023, Resonandina has regularly used crowdfunding alongside institutional lenders to finance new projects, attracting more than 6,000 crowd investors. The company has built a solid payment track record towards its crowd investors since then.

Read more

Your investment made under the Regulation (EU) 2020/1503 of the European Parliament and of the Council is not protected by the deposit guarantee schemes etablished under Directive 2024/49/EU (Deposit Guarantee Schemes Directive). Your investment is also not protected by the investor compensation schemes established under Directive 97/9/EC (Investor Compensation Schemes Directive).

Floriaan van Bemmelen, CEO, Resonandina

“At Resonandina, we make advanced diagnostics and treatment like radiotherapy accessible where they are needed most. Our sustainable medical lease model enables hospitals to deploy high-end equipment without heavy upfront investment.

Since 2023, more than 6,000 investors have supported our growth across multiple successful campaigns. With this 9th round, we continue expanding our installed base by financing a new Linear Accelerator project in Latin America, further strengthening regional cancer treatment capacity.

We appreciate the continued trust of our investor community and look forward to creating impact together.”

Floriaan van Bemmelen, CEO, Resonandina

Investment information

Days to invest:
20
Investing round ends:
19/10/2026
Type:
Bond
Subordinated:
no
Invested so far:
€995,750.00
Price per bond:
€250.00
Transaction costs:
1.50 %
Min offer:
1 Unit
Maximum issue size:
€2,500,000
in 10,000 Units
Interest:
semi-annual
Repayment:
semi-annual
after 6 Months
ISIN:
DE000A4E1E16
Broker:
Oneplanetcrowd International B.V
License:
ECSPR

About Resonandina

⌛

Developments since the last funding round with Invesdor

You already know this company, but want to see what has changed since you last invested? Here you can follow how Resonandina has progressed operationally and financially since the previous crowdfunding campaign. Read the latest developments ➜

Resonandina: Problem, Solution, Market

Problem

Life‑saving diagnostics blocked by lack of capital

Many hospitals in emerging markets lack access to capital-intensive diagnostic and radiotherapy equipment despite clear medical demand.

High upfront investment costs, limited access to long‑term financing and a lack of in‑house technical expertise mean that even where medical demand is clear, hospitals cannot easily acquire or operate such equipment. As a result, patients often face long travel distances, delayed diagnosis and limited access to modern cancer treatment.


Solution

All‑inclusive pay‑per‑use leasing unlocks advanced diagnostics and treatment

Resonandina enables hospitals to deploy high-end medical equipment through long-term pay‑per‑use lease agreements without large upfront investments. Capital‑intensive equipment becomes affordable because hospitals pay smaller recurring amounts instead of a single large lump sum.

Resonandina offers an all‑inclusive package that covers project design, investment, installation, training, full maintenance and lifecycle management (including upgrades, reuse and recycling). The hospital retains all medical‑related responsibilities such as patient logistics, quality management, liability and (insurance) invoicing.

In this way, hospitals can deploy advanced equipment so that diagnostics become more affordable and accessible. This leads to healthier populations and fewer long‑distance journeys for treatment.


Business model

Usage‑based leasing with long‑term, asset‑backed cash flows

Recurring revenues are generated through usage‑based payments under long‑term (typically 8+ year) contracts with minimum volume commitments. After an initial ramp‑up period, hospitals pay a fee per scan or treatment, ensuring that Resonandina’s income is closely linked to actual equipment utilization.

For every €1 million invested in medical equipment, Resonandina typically generates approximately €250,000–€350,000 in annual recurring revenue, depending on modality and utilization levels, with an average payback period of around four years and an economic lifetime of 10–15+ years with proper maintenance.


Market

Structural growth in diagnostic and radiotherapy demand

In Latin America and the Caribbean, radiotherapy and advanced diagnostic imaging capacity remain well below international benchmark levels. Around 800 Linear Accelerators are currently installed; to approach benchmark coverage, more than 1,600 additional systems would be needed, on top of replacements for ageing equipment. A significant part of the existing installed base is already older than ten years. At the same time, use of modern imaging continues to rise, driven by population growth, urbanisation and expanding healthcare coverage. Resonandina positions its activities in this under-supplied market environment, where demand for equipment is growing structurally over the long term.


Competitors

Traditional equipment sales leave a financing gap

Advanced medical equipment is usually supplied by large original equipment manufacturers (OEMs) such as GE Healthcare, Varian/Siemens Healthineers and Philips, who sell systems upfront, often with local bank financing. These models require strong balance sheets and additional collaterals, which many hospitals in emerging markets do not have. Resonandina operates in this gap by keeping ownership of the equipment and offering long term pay per use leasing that bundles financing, installation and lifecycle management into one integrated solution.


Impact

Bringing advanced care closer to patients

Resonandina’s core contribution is to SDG 3 (Good health and wellbeing) by bringing advanced diagnostic and radiotherapy equipment (MRI, CT, PET/CT and Linear Accelerators) to regions where such infrastructure is limited or absent. Earlier and more precise diagnosis, together with access to local radiotherapy, can significantly improve treatment pathways, especially for patients who would otherwise need to travel long distances for care.

By installing these services, Resonandina also indirectly supports SDG 7 (Affordable and clean energy). When patients no longer need to travel hundreds of kilometers for diagnosis or cancer treatment, transport related fuel use and emissions decrease. Each installed system therefore serves a substantial regional population, strengthens the local healthcare ecosystem and contributes to a more efficient and resource conscious delivery of care.

How does it work?

This model allows hospitals to offer advanced diagnostic and radiotherapy services without the financial burden of purchasing equipment outright. By preserving operational liquidity and providing flexibility in financial planning, Resonandina ensures healthcare providers can focus on patient care.

The pay-per-use system, combined with volume discounts, incentivizes hospitals to maximize equipment usage, improving both efficiency and profitability. Resonandina offers a practical, transparent, and affordable financial solution for hospitals, while creating predictable recurring revenues.

1

Acquisition and installation

Resonandina purchases the high-value medical equipment and installs it at the hospital. Together with the OEM, the team organizes project design, site preparation and connection to existing systems. The equipment remains owned by Resonandina for the entire lease period.

2

Pay-per-use leasing

Once installed, the hospital operates the equipment and pays a fee per scan or treatment. The cost per procedure decreases as usage increases, which encourages efficient use of the equipment and allows more patients to be served. Over time, the equipment typically earns back its cost in a few years, while it can remain in use much longer with proper maintenance.

3

Minimum volume guarantee

After an initial ramp-up period, the hospital commits to a minimum number of scans or treatments. This minimum volume is designed so that Resonandina can cover its financing obligations, providing downside protection in the early years of a project and supporting stable debt servicing.

4

Revenue generation

Hospitals invoice patients or insurers based on local tariffs. These revenues cover operating costs and will generate additional profit for the hospital, while Resonandina receives the agreed recurring payments under the lease contract. In this way, hospitals can focus on patient care while improving operational efficiency and long-term financial sustainability.

Management

Resonandina is led by an experienced founder‑driven team that combines medical, financial and operational expertise in Latin American healthcare markets. The management team has backgrounds in clinical practice, hospital management, project finance and cross‑border operations, providing the skills needed to structure complex medical lease projects and manage a growing international portfolio.

first name last name, position

Floriaan van Bemmelen
CEO / Chairman

Since becoming CEO of Resonandina in 2015, Floriaan van Bemmelen has significantly shaped the company's trajectory. With a background as a general practitioner and director roles in a hospital, an MRI center, and an insurance company, he brings a comprehensive understanding of the healthcare sector. His leadership focuses on enhancing diagnostic and treatment technologies and expanding market reach, ensuring that Resonandina remains at the forefront of medical accessibility innovation. Floriaan's strategic vision and deep industry knowledge have been pivotal in driving the company’s growth and maintaining its competitive edge in the field.

first name last name, position

Antonio Pimentel
COO

Antonio has significant operational experience managing complex projects within a financial institution in the Dominican Republic. With roots in both the U.S. and the Caribbean, he brings a unique perspective and deep understanding of regional markets. Antonio’s expertise is invaluable to Resonandina, as he offers operational insights that help navigate the complexities of cross-border projects, ensuring smooth execution and alignment with local market dynamics. His background enhances the company’s ability to handle intricate operational challenges in diverse geographical regions.

first name last name, position

Luis del Valle
CFO

Luis is a seasoned finance professional with extensive experience in funding start-ups and scale-ups. His expertise spans across international construction and service companies, with a strong focus on managing large-scale projects in Colombia. Luis brings invaluable knowledge to Resonandina, combining his deep understanding of project financing with practical insights into scaling operations in emerging markets. His background ensures that Resonandina has the financial strategy and operational know-how to drive sustainable growth and manage complex ventures.

Company structure

Ownership and governance

Resonandina Holanda B.V. is the Dutch holding company of the Resonandina group. It is fully owned by QMED B.V., a private holding company controlled by founder and CEO Floriaan van Bemmelen and his family. This structure concentrates strategic control and capital allocation at holding level while the operating entities execute projects in their local markets.

Group structure

Investors in this bond lend to Resonandina Holanda B.V. The holding company owns a network of subsidiaries that sign local lease contracts with hospitals and operate the medical equipment under long term agreements.

As of 31 December 2025, the group includes operating entities in Bolivia, Brazil, Chile, Colombia, Peru, Ecuador, the Dominican Republic, Mexico, Panama as well as the USA and Puerto Rico. These subsidiaries are majority owned by Resonandina Holanda B.V. and form the platform through which the international project portfolio is managed.

Holding company

Resonandina Holands BV
The Netherlands

Ownership: 100%

Resonandina Bolivia SRL

Bolivia

Ownership: 100%

Resonandina Chile ltda

Chile

Ownership: 100%

Resonandina Brasil ltda

Brazil

Ownership: 100%

Resonandina Peru SRL

Peru

Ownership: 100%

Resonandina Colombia SAS

Colombia

Ownership: 100%

Fideicomiso Resonandina Ecuador

Ecuador

Ownership: 100%

Fideicomiso Resonandina Dominicana

Dominican Republic

Ownership: 100%

Resonandina SA (panama)

Panama

Ownership: 100%

Resonandina LLC (USA)

USA

Ownership: 100%

Resonandina Mexico S. De RL.de CV

Mexico

Ownership: 100%

Use of funds

The proceeds of this 9th bond round will be used to finance a new Linear Accelerator (Linac) “ecosystem” project in Colombia, including CT simulator and mammograph. The Linac is used in radiotherapy to treat cancer and will be installed at a partner clinic where regional treatment capacity is currently limited. Depending on the total amount raised, the funds will either co-finance or fully finance the project within Resonandina’s established medical lease structure.

Minimum scenario

Scenario I: €500,000 (minimum subscription)

In this scenario, the funds will be used to co-finance the Linac project in Colombia alongside additional group financing.

Use of funds

  • 100% – Equipment acquisition (partial financing)
    Contribution to the purchase of the Linear Accelerator.

This scenario enables the structured implementation of the Linac project and the start of local radiotherapy services.

Maximum scenario

Scenario II: €2,500,000 (full subscription)

In this scenario, the funds will be used to fully finance the Linac project in Colombia, including acquisition and all related project costs.

Use of funds

  • 60% – Full equipment acquisition
    Purchase of the Linear Accelerator.
  • 20% – Additional equipment and working capital during ramp-up phase
    Purchase of CT simulator and Mammograph. Operational buffer during the initial months of project execution and financial costs..
  • 15% – Installation and technical implementation
    Transport, customs clearance, engineering and certified installation.
  • 5% – Commissioning and training
    System integration, testing and training of local staff in collaboration with OEM partners.

This scenario allows Resonandina to fully implement the Linac project within its established medical lease structure and expand radiotherapy capacity in the region.

Developments at Resonandina since the last crowdfunding

The company’s development over the past year reflects continued growth and further professionalization. Key developments include:

  • Financial performance: EBITDA increased from approximately €1,8 million in 2024 to around €2,6 million in 2025. For 2026, EBITDA is expected maintain the same level due to delayed installation of projects.
  • Project delivery: In 2025, five projects were successfully installed, bringing the total to 16 active projects. Several installations are awaiting client readiness and are expected to be completed in 2026 and 2027. Currently, 12 projects are signed and in the installation phase. These timing shifts affect short-term results but do not change the overall projections.
  • Strengthened capital base: 2025 solvency increased to approximately 22%, supported by retained earnings and the formalization of a €2 million subordinated loan.
  • Market expansion: In cooperation with Varian (Siemens Healthineers), new contracts have been signed in underserved regions of Peru, Colombia and Mexico. Also key prospects in Brazil and Caribbean are in focus. 
  • Organizational development: The team has expanded and internal processes have been further professionalized, reducing operational dependency on individual management members and strengthening scalability.

Together, these developments indicate steady operational growth and increasing maturity of the organization compared to earlier funding rounds..

Financial figures & growth

Actual and planned figures

Get an insight in to the company's financial figures, such as turnover and earnings development. Learn more about the growth forecast.

Login Sign up

Security & Risks

Security

The following collateral is provided for this funding round: a 100 % guarantee from Resonandina Colombia SAS; a right of pledge on the equipment to be leased as specified in the KIIS; and a right of pledge on the guarantor’s claims against the respective lessees. The value of the collateral may fluctuate, particularly in the event of a default, which may result in a lower return. Detailed information on the collateral can be found in the KIIS in the documents section for this funding round.

Risk summary (simplified)

Investing in growth companies through bonds involves very high risks. You can lose part or all of the money you invest.
The following text is a short and strongly simplified overview of selected risks of an investment in Resonandina Holanda B.V..
It is not complete and does not replace the detailed description of risks in the Key Investment Information Sheet (KIIS)..
Before you invest, you must read the KIIS in full and with care and check whether you can understand and bear all of the risks described there.
If there are any differences between this summary and the KIIS, only the KIIS is legally binding.


Key Risk Areas (Short Overview)

Business, execution and management risk
The business depends on leasing medical imaging equipment to hospitals and on the expected number of uses. If lease income is lower than planned, or funding for equipment is not available, the company may not be able to pay interest or repay the bonds in full. Delays or failures by suppliers, service providers, customers or equipment may also reduce income. The business also depends on key management, including its sole CEO/Managing Director.
Market, legal and currency risk
Demand for leased medical imaging devices may not develop as expected and hospitals may not enter into lease agreements. Economic changes, legal changes or proceedings could harm the business. The group borrows and receives income in different currencies and pays for equipment in US dollars. Exchange-rate changes may reduce cash available in euros for the bonds.
Default, return and liquidity risk
The project owner may be unable to meet its payment obligations and could become insolvent. In that case, you may lose part or all of the money you invest. Payments also depend on the value and enforceability of the collateral. Returns may be lower, delayed or not paid at all, and inflation, exchange rates, costs and your tax position can reduce your return. The bonds cannot normally be terminated early, and there is no stock exchange or liquid secondary market. You may have to hold them until maturity or sell at a loss.
Platform, investor-rights and technology risk
The platform may be unavailable or close, which can delay communication and payments, although your contractual claim against the project owner remains. The bonds give no voting or participation rights. Bond terms can be changed by the required majority of bondholders. The electronic register, digital safe deposit box and related technology may have faults, be attacked or fail. This could limit access to or transfers of the bonds, and in the worst case lead to a permanent loss of access.

A complete and detailed description of all risk factors can be found only in the KIIS in the documents section of this funding round.


-----End of marketing content-----

Documents

Investment related documents

Log in for more information.

Updates

There are currently no updates available.

This section will be regularly updated with new, project-relevant information as the financing progresses. To be informed about new updates in a timely manner, subscribe to our newsletter.

Invesdor is a Eurocrowd platform member.

Ausgezeichnet als Top-Innovator 2021

Winner of the Golden Bull as the best
Crowdfunding platform 2023.

ECSP lizensiert

Invesdor is licensed under the
ECSP regulation of the EU.